XAIR.NASDAQBeyond Air, INC

8-K: Beyond Air Secures $11.5 Million Loan with CEO and Director Participation

Sentiment:

Current Report


Beyond Air has entered into a binding term sheet for a $11.5 million secured loan with its CEO and a director, featuring a 15% interest rate and a royalty on net sales.

Capital raiseThe company is raising $11.5 million through a secured loan.The company will issue warrants to the lenders to purchase common stock at an exercise price of $0.3793 per share.
Worse than expectedThe high interest rate of 15% and the 8% royalty on net sales are worse than typical financing terms, indicating a higher cost of capital for the company.

Summary

  • Beyond Air has agreed to a $11.5 million secured loan with certain lenders, including its CEO and a director.
  • The loan has a ten-year term and an annual interest rate of 15%, payable in kind until July 2026.
  • Starting July 2026, the lenders will receive an 8% royalty on the company's net sales until the loan is fully repaid.
  • The loan is secured by substantially all of Beyond Air's assets.
  • The lenders will also receive warrants to purchase common stock at an exercise price of $0.3793 per share.
  • The company expects to finalize the loan agreement and issue the warrants by October 31, 2024.

Sentiment

Score: 4

Explanation: The high interest rate and royalty payments, along with the security on all assets, suggest a challenging financial situation for the company. While the funding is positive, the terms are not favorable.

Positives

  • The loan provides Beyond Air with $11.5 million in funding.
  • The loan was approved by independent directors after a recommendation from an independent investment bank.

Negatives

  • The 15% interest rate is relatively high.
  • The 8% royalty on net sales will reduce future revenue.
  • The loan is secured by substantially all of the company's assets, increasing risk for the company.

Risks

  • The high interest rate and royalty payments could strain the company's finances.
  • Securing the loan with substantially all assets increases the risk of asset loss in case of default.
  • The issuance of warrants could dilute existing shareholders' equity.

Future Outlook

The company expects to finalize the loan agreement and issue warrants by October 31, 2024.

Management Comments

  • The term sheet was approved by each of the company's independent and disinterested directors, following the receipt of a recommendation from an independent investment bank.

Industry Context

This type of financing, involving a company's CEO and a director, is not uncommon for smaller, growth-stage companies that may have difficulty accessing traditional financing. The high interest rate and royalty suggest the company may be considered a higher risk borrower.

Comparison to Industry Standards

  • The 15% interest rate is significantly higher than typical bank loans, which often range from 5% to 10% for established companies.
  • The 8% royalty on net sales is also a substantial cost, which is not a standard feature of most loans.
  • Comparable companies in the biotech or medical device space often secure funding through venture capital, private equity, or strategic partnerships, which may have different terms and conditions.
  • The involvement of the CEO and a director as lenders is a related party transaction that requires careful scrutiny to ensure fair terms for the company and its shareholders.

Related Party Transactions

  • The loan involves the company's CEO and a director as lenders.

Stakeholder Impact

  • Shareholders may experience dilution due to the issuance of warrants.
  • The company's financial flexibility may be reduced due to the debt obligations and security on assets.
  • The royalty payments will reduce future revenue available to the company.

Next Steps

  • The company will finalize the loan and security agreement.
  • The company will issue warrants to the lenders.
  • The company will file the term sheet as an exhibit to its Quarterly Report on Form 10-Q.

Key Dates

DateDescription
September 27, 2024Date of the binding term sheet for the secured loan.
September 30, 2024End of the quarter for which the term sheet will be filed as an exhibit in the 10-Q.
October 2, 2024Date the 8-K report was signed.
October 31, 2024Expected date for finalizing the loan agreement and issuing warrants.
July 2026Start date for royalty payments and end of interest payment in kind.

Keywords

loan, secured loan, financing, warrants, royalty, interest rate, debt, Beyond Air

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.